NCT06472388View on ClinicalTrials.gov

Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 24, 2024

Primary Completion Date

May 20, 2026

Study Completion Date

December 31, 2026

Conditions
Neuroendocrine TumorsProgressionNeuroendocrine Tumor Grade 1Neuroendocrine Tumor Grade 2Neuroendocrine Tumor of PancreasNeuroendocrine Tumor of the LungNeuroendocrine Tumor Carcinoid
Interventions
DRUG

Everolimus 5 MG

oral everolimus 5 mg/daily

Trial Locations (2)

01509010

RECRUITING

AC Camargo Cancer Center, São Paulo

RECRUITING

AC Camargo Cancer Center, São Paulo

All Listed Sponsors
lead

AC Camargo Cancer Center

OTHER